Fig. 7

Characteristics of si-cSERPINE2-NPs and therapeutic efficacy of si-cSERPINE2-NPs in breast cancer in vivo. a Schematic illustration of the si-cSERPINE2-NPs. b Size distribution of the si-cSERPINE2-NPs in the aqueous solution detected by Dynamic light scattering (DLS). c Representative TEM images of si-cSERPINE2-NPs. Scale bar, 100 nm. d Zeta potential of si-cSERPINE2-NPs in the aqueous solution detected by DLS. e Stability of si-cSERPINE2-NPs in 10% serum at 37 °C was evaluated by measuring particle size changes with DLS at various time points up to 96 h. f The relative expression of cSERPINE2 in EO771 cells treated with si-cSERPINE2-NPs at different siRNA doses. g The relative expression of cSERPINE2 in EO771 cells treated with PBS, NPs, si-ctrl NPs, si-cSERPINE2-NPs or shcSERPINE2-1. h The relative expression of cSERPINE2 (left) and MALT1 (right) in mTAMs as indicated treatments. i Schematic illustration (upper) of tumor inoculation and different treatments in EO771-Luc orthotopic breast cancer models. Representative bioluminescence images and quantification (lower) of the EO771-Luc orthotopic breast cancer models. j IHC staining of Ki67, CD44 expression and F4/80⁺ macrophages infiltration in the tumor tissues of orthotopic breast cancer models. scale bar, 20 μm. k Schematic illustration (upper) of tumor inoculation and different treatments in EO771 lung metastatic models. Representative H&E images (left) and quantification (right) of lung metastases. Scale bar, 100 μm. l Histological section of the major organs after six consecutive injections of PBS, NPs, si-ctrl NPs or si-cSERPINE2-1-NPs in EO771-luc orthotopic breast cancer models. Scale bar, 20 μm. Data are presented as the means ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001